Back to News
Market Impact: 0.25
Percheron's HMBD-002 Gets FDA Clearance For Blood Cancer Combination Trial
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
Percheron Therapeutics said the FDA cleared an investigator-sponsored trial of HMBD-002 in combination with venetoclax and azacitidine for acute myeloid leukemia and myelodysplastic syndrome. The announcement is a clinical-development milestone; the article provided no trial results or financial figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
More News
- Kimberly-Clark closes its acquisition of Tylenol maker Kenvue. What to expect next
- In one of the largest deals in tech history, Marvell buys Lumentum for $115B
- How Trump’s trade policy is handing Asia to Beijing
- RA Capital Management sells $9.13M in Lenz Therapeutics shares
- Karyopharm stock rating cut to neutral by Rodman on bankruptcy
- Apple may try to increase revenue by doing…something with third-party AI apps